Literature DB >> 12204709

Latanoprost for the treatment of pediatric glaucoma.

Laura B Enyedi1, Sharon F Freedman.   

Abstract

Latanoprost is a prostaglandin F(2alpha) analog that reduces intraocular pressure (IOP) by 20-40% in adults with open-angle glaucoma or ocular hypertension. The efficacy and safety of latanoprost in children has not been widely reported, but there are at least three peer-reviewed publications involving the use of this drug in the treatment of pediatric patients with glaucoma. Most of the patients in these studies showed disappointingly little IOP effect from this drug, but some children, particularly older children and those with juvenile-onset open-angle glaucoma, do have a significant ocular hypotensive effect with latanoprost. Systemic and ocular side effects in children on latanoprost are infrequent and mild.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12204709     DOI: 10.1016/s0039-6257(02)00303-x

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  10 in total

Review 1.  Surgical interventions for primary congenital glaucoma.

Authors:  Deepta Ghate; Xue Wang
Journal:  Cochrane Database Syst Rev       Date:  2015-01-30

2.  Consequences of Puberty on Efficacy of Intraocular Pressure-Lowering Drugs in Male Dutch-Belted Rabbits.

Authors:  Cassandra L Hays; Kingsley C Okafor; Shan Fan; Robin High; Dhirendra P Singh; Carol B Toris
Journal:  J Ocul Pharmacol Ther       Date:  2017-08-18       Impact factor: 2.671

Review 3.  Pharmacologic management of glaucoma in childhood.

Authors:  Will Moore; Ken K Nischal
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

4.  Long-term efficacy of latanoprost in primary congenital glaucoma.

Authors:  M G Uva; T Avitabile; M Reibaldi; C Bucolo; F Drago; L Quaranta; E Lionetti; A Longo
Journal:  Eye (Lond)       Date:  2013-10-25       Impact factor: 3.775

5.  [Depression of respiration via toxic effects on the central nervous system following use of topical brimonidine in an infant with congenital glaucoma].

Authors:  K Heimann; T Peschgens; U Merz; H Hoernchen; T Wenzl
Journal:  Ophthalmologe       Date:  2007-06       Impact factor: 1.059

Review 6.  Juvenile-onset open-angle glaucoma - A clinical and genetic update.

Authors:  Harathy Selvan; Shikha Gupta; Janey L Wiggs; Viney Gupta
Journal:  Surv Ophthalmol       Date:  2021-09-16       Impact factor: 6.197

7.  Ahmed glaucoma valve in children: A review.

Authors:  Nariman Nassiri; Kouros Nouri-Mahdavi; Anne L Coleman
Journal:  Saudi J Ophthalmol       Date:  2011-07-30

8.  Pharmacogenetics of ophthalmic topical beta-blockers.

Authors:  Duska J Sidjanin; Catherine A McCarty; Richard Patchett; Edward Smith; Russell A Wilke
Journal:  Per Med       Date:  2008       Impact factor: 2.512

9.  Surgical interventions for primary congenital glaucoma.

Authors:  Meghal Gagrani; Itika Garg; Deepta Ghate
Journal:  Cochrane Database Syst Rev       Date:  2020-08-25

Review 10.  Rare Diseases Leading to Childhood Glaucoma: Epidemiology, Pathophysiogenesis, and Management.

Authors:  Solmaz Abdolrahimzadeh; Valeria Fameli; Roberto Mollo; Maria Teresa Contestabile; Andrea Perdicchi; Santi Maria Recupero
Journal:  Biomed Res Int       Date:  2015-09-16       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.